Below are upcoming trade shows and conferences that AnaBios will be attending. Be sure to check back often to view our upcoming events. Want to schedule a meeting with an AnaBios representative? Email us at firstname.lastname@example.org.
WEBINAR | Saturated & Monounsaturated Fatty Acids Regulate Mitochondrial Dynamics & Nerve Function in Murine Models of Prediabetes
OCTOBER 22, 2020
Join us on Thursday, October 22nd, at 8 AM PST for our new webinar, “Saturated & Monounsaturated Fatty Acids Regulate Mitochondrial Dynamics & Nerve Function in Murine Models of Prediabetes,” presented by Dr. Amy Rumora, Postdoctoral Fellow at the University of Michigan School of Medicine. Peripheral neuropathy (PN) is the most common complication of type 2 diabetes (T2D) and prediabetes. Patients with PN experience a length-dependent loss of sensation in their limbs due to peripheral nerve damage. The severity of PN in T2D and prediabetic patients correlates with dyslipidemia, indicating that dietary fatty acids contribute to PN pathogenesis. Dr. Rumora and her team examined the impact of dietary saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) on nerve function in a murine model of prediabetes. Interestingly, mice fed an SFA-rich high fat diet (HFD) developed robust PN while mice switched to a MUFA-rich HFD had improved nerve function. In vitro, SFA treatments impaired mitochondrial trafficking and function in cultured sensory neurons while MUFA supplementation prevented mitochondrial dysfunction through the formation of lipid droplets. These data suggest that SFA-induced mitochondrial dysfunction contributes to PN development, and that MUFAs restore nerve function and prevent mitochondrial dysfunction through lipid droplet formation. Click here to view more information and register.
WEBINAR | Discovery & Characterization of ORM-11372: Implications for Heart Failure Drug Discovery
OCTOBER 29, 2020
Join us on Thursday, October 29th, at 8 am PST (11 am EST) for our new webinar, “Discovery & Characterization of ORM-11372 (A Unique and Positive Inotropic Sodium-Calcium Exchanger/Inhibitor: Implications for Heart Failure Drug Discovery,” presented by Jouko Levijoki, Senior Research Scientist at Orion Corporation. The lack of selective sodium-calcium exchanger (NCX) inhibitors has hampered the exploration of physiological and pathophysiological roles of cardiac NCX 1.1. Levijoki and his team aimed to discover a more potent and selective drug like NCX 1.1. inhibitor. ORM-11372, a unique, novel, and potent inhibitor of human and rat NCX 1.1, is a positive inotropic compound. NCX inhibition can induce clinically relevant improvements in left ventricular contractions without affecting relaxation, heart rate or blood pressure–without pro-arrhythmic risk. Click here to view more information and register.